NO964073L - Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter - Google Patents
Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekterInfo
- Publication number
- NO964073L NO964073L NO964073A NO964073A NO964073L NO 964073 L NO964073 L NO 964073L NO 964073 A NO964073 A NO 964073A NO 964073 A NO964073 A NO 964073A NO 964073 L NO964073 L NO 964073L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- mitochondrial
- methods
- therapy
- mitochondria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
Abstract
Foreliggende oppfinnelse vedrører genetiske mutasjoner i mitokondriske cytokrom-c-oksydasegener som følger sammen med Alzheimers sykdom (AD), diabetes mellitus, Parkinsons sykdom og andre sykdommer av mitokondrisk opphav. Oppfinnelsen frembringer fremgangsmåter ved påvisning av disse mutasjoner, enten før eller etter opptreden av kliniske symptomer. Oppfinnelsen frembrin- ger ytterligere behandling av cytokrom-c-oksydase- dysfunksjon. Cybridcellelinjer som er nyttige som modellsystemer ved undersøkelsen av lidelser som er forbundet med mitokondriske defekter, beskrives også. Cybridene konstrueres ved å behandle udødelige celle- linjer med et middel som irreversibelt setter den mitokondriske elektrontransport ut av funksjon og deretter å transfektere cellene med mitokondria som er blitt isolert fra sykdomsrammede vevprøver. En slik cybrid ble konstruert under anvendelse av neuroblastom- celler og mitokondria fra en pasient som led av Alzhei- mers sykdom. Fremgangsmåter ved anvendelse av slike cybrider ved testing av legemidlers og terapiers nytte ved behandling av slike lidelser, frembringes også. Det frembringes i tillegg også cybriddyr, fremgangsmåter ved deres fremstilling og fremgangsmåter ved deres anvendelse innen legemiddel- og terapitesting.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/219,842 US5565323A (en) | 1994-03-30 | 1994-03-30 | Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease |
US08/397,808 US5888498A (en) | 1995-03-03 | 1995-03-03 | Cellular and animal models for diseases associated with mitochondrial defects |
PCT/US1995/004063 WO1995026973A1 (en) | 1994-03-30 | 1995-03-30 | Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects |
Publications (2)
Publication Number | Publication Date |
---|---|
NO964073D0 NO964073D0 (no) | 1996-09-27 |
NO964073L true NO964073L (no) | 1996-11-29 |
Family
ID=26914309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO964073A NO964073L (no) | 1994-03-30 | 1996-09-27 | Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter |
Country Status (12)
Country | Link |
---|---|
US (1) | US20010021526A1 (no) |
EP (1) | EP0751951A4 (no) |
JP (1) | JPH09511398A (no) |
CN (1) | CN1150433A (no) |
AU (1) | AU705230B2 (no) |
BR (1) | BR9507241A (no) |
CA (1) | CA2186636A1 (no) |
FI (1) | FI963884A (no) |
MX (1) | MX9604400A (no) |
NO (1) | NO964073L (no) |
NZ (1) | NZ283660A (no) |
WO (1) | WO1995026973A1 (no) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6027880A (en) * | 1995-08-02 | 2000-02-22 | Affymetrix, Inc. | Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis |
US7115364B1 (en) | 1993-10-26 | 2006-10-03 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US20060229824A1 (en) | 1993-10-26 | 2006-10-12 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes |
US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
US5840493A (en) * | 1994-03-30 | 1998-11-24 | Mitokor | Mitochondrial DNA mutations that segregate with late onset diabetes mellitus |
US6291172B1 (en) | 1995-03-03 | 2001-09-18 | Mitokor | Diagnostic assay for diabetes mellitus based on mutational burden |
WO1996030545A1 (en) * | 1995-03-24 | 1996-10-03 | Mitokor | Mutation detection by differential primer extension of mutant and wildtype target sequences |
US6391550B1 (en) | 1996-09-19 | 2002-05-21 | Affymetrix, Inc. | Identification of molecular sequence signatures and methods involving the same |
GB9620028D0 (en) | 1996-09-26 | 1996-11-13 | Ludwig Inst Cancer Res | Factors which interact with oncoproteins |
US20020106354A1 (en) * | 1998-04-28 | 2002-08-08 | Christen M. Anderson | Cellular and animal models for diseases associated with altered mitochondrial function |
US6441149B1 (en) * | 1998-06-15 | 2002-08-27 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6489095B2 (en) | 1998-06-15 | 2002-12-03 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
EP1171137B1 (en) * | 1999-02-23 | 2007-12-26 | The Regents of the University of California | Use of triacetyluridine for the treatment of mitochondrial disorders |
AU3900600A (en) * | 1999-03-16 | 2000-10-04 | Mitokor | Differential expression of organellar gene products |
FR2798556B1 (fr) * | 1999-09-17 | 2004-02-27 | Aventis Pharma Sa | Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux |
JP2003509071A (ja) * | 1999-09-17 | 2003-03-11 | アバンテイス・フアルマ・エス・アー | アミロイド斑およびミトコンドリア機能障害を示すアルツハイマー病の新規の動物モデル |
CN1277995A (zh) * | 1999-11-22 | 2000-12-27 | 上海博容基因开发有限公司 | 一种新的多肽——人细胞色素氧化酶相关蛋白37和编码这种多肽的多核苷酸 |
DK1229130T3 (en) * | 2000-12-04 | 2014-02-24 | Primagen B V | TEST BASED ON nucleic acids OF ENDOSYMBIONTISKE, cellular organelles |
JP2003116576A (ja) * | 2001-10-17 | 2003-04-22 | Gifu International Institute Of Biotechnology | ヒトミトコンドリアdnaを用いた遺伝子検出方法 |
US7888334B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
US7888335B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
WO2006099050A2 (en) * | 2005-03-09 | 2006-09-21 | Cepheid | Polar dyes |
US9603872B2 (en) * | 2007-05-02 | 2017-03-28 | The McLeon Hospital Corporation | Methods and compositions for mitochondrial replacement therapy |
EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
CA2886921A1 (en) * | 2012-10-05 | 2014-04-10 | Neurovive Pharmaceutical Ab | Mitochondrial toxicity test |
KR101556439B1 (ko) | 2013-07-01 | 2015-10-15 | 서울대학교산학협력단 | 미토콘드리아 역행성 신호 경로와 관련된 RXRα의 기능 및 용도 |
KR20200034668A (ko) | 2017-05-08 | 2020-03-31 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 융합을 촉진시키기 위한 조성물 및 그의 용도 |
CN107746889A (zh) * | 2017-07-17 | 2018-03-02 | 国家海洋局北海环境监测中心 | 用于扩增底栖多毛类环节动物线粒体co i基因片段的引物 |
JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
EP3851112A4 (en) * | 2018-09-14 | 2022-07-27 | Luca Science Inc. | TRANSPLANTATION OF MITOCHONDRIA IN A LYMPHOID ORGAN AND ASSOCIATED COMPOSITION |
CN109796527B (zh) * | 2019-03-07 | 2020-09-04 | 广西大学 | 一种红麻线粒体蛋白cox3抗原多肽及制备多克隆抗体的方法和应用 |
CN111034736B (zh) * | 2019-12-13 | 2021-04-06 | 西北农林科技大学 | 一种杀虫组合物及其应用 |
CN111579763B (zh) * | 2020-04-09 | 2023-04-07 | 北京博瑞世安科技有限公司 | 检测白细胞线粒体呼吸功能的方法及检测肾阴虚症的方法 |
CN111781175B (zh) * | 2020-06-18 | 2023-04-21 | 中国人民解放军军事科学院国防科技创新研究院 | 一种用于提高细胞中线粒体活性的方法及装置和应用 |
WO2024015951A2 (en) * | 2022-07-15 | 2024-01-18 | Seq Biomarque, Llc | Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease |
CN115960087B (zh) * | 2022-09-16 | 2024-06-07 | 浙江工业大学 | 黏度响应型双光子荧光化合物及其合成与应用 |
CN117384269B (zh) * | 2023-09-21 | 2024-06-18 | 南方医科大学南方医院 | 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185244A (en) * | 1989-12-08 | 1993-02-09 | Emory University | Genetic test for hereditary neuromuscular disease |
US5296349A (en) * | 1990-06-14 | 1994-03-22 | Emory University | Molecular genetic test for myoclonic epilepsy |
US5494794A (en) * | 1992-10-20 | 1996-02-27 | Emory University | Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease |
US5506101A (en) * | 1993-06-30 | 1996-04-09 | Cedars-Sinai Medical Center | Method for detection of susceptibility mutations for ototoxic deafness |
-
1995
- 1995-03-30 JP JP7525887A patent/JPH09511398A/ja active Pending
- 1995-03-30 CA CA002186636A patent/CA2186636A1/en not_active Abandoned
- 1995-03-30 AU AU22042/95A patent/AU705230B2/en not_active Ceased
- 1995-03-30 BR BR9507241A patent/BR9507241A/pt not_active Application Discontinuation
- 1995-03-30 WO PCT/US1995/004063 patent/WO1995026973A1/en not_active Application Discontinuation
- 1995-03-30 MX MX9604400A patent/MX9604400A/es not_active Application Discontinuation
- 1995-03-30 EP EP95914998A patent/EP0751951A4/en not_active Withdrawn
- 1995-03-30 NZ NZ283660A patent/NZ283660A/en unknown
- 1995-03-30 CN CN95193362A patent/CN1150433A/zh active Pending
-
1996
- 1996-09-27 NO NO964073A patent/NO964073L/no not_active Application Discontinuation
- 1996-09-27 FI FI963884A patent/FI963884A/fi unknown
-
2001
- 2001-04-02 US US09/825,525 patent/US20010021526A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
FI963884A (fi) | 1996-11-26 |
NO964073D0 (no) | 1996-09-27 |
MX9604400A (es) | 1997-12-31 |
EP0751951A4 (en) | 2000-05-03 |
WO1995026973A1 (en) | 1995-10-12 |
JPH09511398A (ja) | 1997-11-18 |
AU2204295A (en) | 1995-10-23 |
US20010021526A1 (en) | 2001-09-13 |
CN1150433A (zh) | 1997-05-21 |
FI963884A0 (fi) | 1996-09-27 |
EP0751951A1 (en) | 1997-01-08 |
CA2186636A1 (en) | 1995-10-12 |
AU705230B2 (en) | 1999-05-20 |
NZ283660A (en) | 1998-07-28 |
BR9507241A (pt) | 1997-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO964073L (no) | Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter | |
Ortuño‐Lizarán et al. | Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity | |
Davis et al. | Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala | |
Pierce et al. | Ibotenic acid lesions of the dorsal prefrontal cortex disrupt the expression of behavioral sensitization to cocaine | |
Perry et al. | Decreased imipramine binding in the brains of patients with depressive illness | |
Klivenyi et al. | Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis | |
Chandler et al. | Identification and distribution of projections from monoaminergic and cholinergic nuclei to functionally differentiated subregions of prefrontal cortex | |
Temlett et al. | Increased iron in the substantia nigra compacta of the MPTP‐lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis | |
Shimohama et al. | Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer‐type dementia | |
Valcana et al. | EFFECT OF HYPOTHYROIDISM ON IONIC METABOLISM AND Na‐K ACTIVATED ATP PHOSPHOHYDROLASE ACTIVITY IN THE DEVELOPING RAT BRAIN 1 | |
Norgren Jr et al. | Herpes simplex virus as a transneuronal tracer | |
Forest et al. | Protection against β‐amyloid neurotoxicity by a non‐toxic endogenous N‐terminal β‐amyloid fragment and its active hexapeptide core sequence | |
Dorman et al. | Fertility and developmental neurotoxicity effects of inhaled hydrogen sulfide in Sprague–Dawley rats | |
Caine | Gilles de la Tourette's syndrome: a review of clinical and research studies and consideration of future directions for investigation | |
Zhang et al. | Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning | |
Natori et al. | THE 11,000-DALTON COMPONENT OF MOUSE II-2 ISOLATION AND IDENTIFCATION | |
NO333437B1 (no) | Fremgangsmate for a isolere et intestinalt kolesterolbindende protein, sammensetning samt anvendelse av sammensetningen | |
McArdle et al. | Accumulation of calcium by normal and dystrophin-deficient mouse muscle during contractile activity in vitro | |
WO2000066782A3 (en) | Diagnostic assay for diabetes mellitus based on mutational burden | |
Wirtshafter et al. | Chemogenetic inhibition of cells in the paramedian midbrain tegmentum increases locomotor activity in rats | |
Dobyns et al. | Deficiency of chromosome 8p21. 1→ 8pter: case report and review of the literature | |
Vuillemin et al. | Pathogenesis of various forms of double outlet right ventricle in mouse fetal trisomy 13 | |
Montpetit et al. | Alteration of neuronal cytoskeletal organization in dorsal root ganglia associated with pyridoxine neurotoxicity | |
Asin et al. | Amphetamine induces Fos-like immunoreactivity in the striatum of primates | |
Vos et al. | Short and long term plasticity after lesioning of the cell body or terminal field area of the dopaminergic mesocorticolimbic system in the rat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |